Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Deep Scientific Insights on Dabigatran Etexilate Mesylate's R&D Progress
Drug Insights
4 min read
Deep Scientific Insights on Dabigatran Etexilate Mesylate's R&D Progress
18 September 2023
This article summarized the latest R&D progress of Dabigatran Etexilate Mesylate, the Mechanism of Action for Dabigatran Etexilate Mesylate, and the drug target R&D trends for Dabigatran Etexilate Mesylate.
Read →
Blue Earth Therapeutics reports encouraging findings from preclinical assessment of 225Ac-rhPSMA-10.1 of Prostate Cancer
Latest Hotspot
3 min read
Blue Earth Therapeutics reports encouraging findings from preclinical assessment of 225Ac-rhPSMA-10.1 of Prostate Cancer
18 September 2023
Blue Earth Therapeutics released preclinical study results on the potency, lipophilicity, absorption, and efficacy of 225Ac-rhPSMA-10.1 in prostate cancer models, compared to 177Lu-rhPSMA-10.1. Both showed strong binding, excellent absorption, and similar lipophilicity.
Read →
An In-depth Analysis of Betahistine Hydrochloride's R&D Progress
Drug Insights
4 min read
An In-depth Analysis of Betahistine Hydrochloride's R&D Progress
18 September 2023
This article summarized the latest R&D progress of Betahistine Hydrochloride, the Mechanism of Action for Betahistine Hydrochloride, and the drug target R&D trends for Betahistine Hydrochloride.
Read →
Migraine Treatment Medication——CGRP antagonists
Migraine Treatment Medication——CGRP antagonists
18 September 2023
CGRP, or calcitonin gene-related peptide, is a neuropeptide that plays a crucial role in the human body.
Read →
Artemether: Detailed Review of its Transformative R&D Success
Drug Insights
4 min read
Artemether: Detailed Review of its Transformative R&D Success
18 September 2023
This article summarized the latest R&D progress of Artemether, the Mechanism of Action for Artemether, and the drug target R&D trends for Artemether.
Read →
Phase 2 Results shows the potential of Vergent Biosciences' Cancer-Specific Fluorescent Imaging Compound to Improve Success of Lung Cancer Surgeries
Latest Hotspot
4 min read
Phase 2 Results shows the potential of Vergent Biosciences' Cancer-Specific Fluorescent Imaging Compound to Improve Success of Lung Cancer Surgeries
18 September 2023
Results from the Phase 2 clinical trial examining VGT-309 indicate that the trial drug could enhance surgeons' capacity to locate hard-to-spot and previously missed tumors in real-time, thereby potentially benefitting patient outcomes.
Read →
 A Comprehensive Review of Zonisamide's R&D Innovations and Drug Target Mechanism
Drug Insights
4 min read
A Comprehensive Review of Zonisamide's R&D Innovations and Drug Target Mechanism
18 September 2023
This article summarized the latest R&D progress of Zonisamide, the Mechanism of Action for Zonisamide, and the drug target R&D trends for Zonisamide.
Read →
Latest Developments in the Research and Development of CGAS Inhibitors
Latest Developments in the Research and Development of CGAS Inhibitors
18 September 2023
CGAS (Cyclic GMP-AMP Synthase) is a crucial enzyme in the human body that plays a vital role in the innate immune response.
Read →
Pharmaceutical Insights: Zoledronic Acid's R&D Progress and its Mechanism of Action on Drug Target
Drug Insights
4 min read
Pharmaceutical Insights: Zoledronic Acid's R&D Progress and its Mechanism of Action on Drug Target
18 September 2023
This article summarized the latest R&D progress of Zoledronic Acid, the Mechanism of Action for Zoledronic Acid, and the drug target R&D trends for Zoledronic Acid.
Read →
Lassen Therapeutics shares new data on LASN01's potential in treating Idiopathic Pulmonary Fibrosis and Thyroid Eye Disease
Latest Hotspot
4 min read
Lassen Therapeutics shares new data on LASN01's potential in treating Idiopathic Pulmonary Fibrosis and Thyroid Eye Disease
17 September 2023
Lassen Therapeutics is developing novel antibody treatments for fibro-inflammatory diseases and cancer, focusing on the IL-11R receptor (LASN01) and interleukin-18 binding proteins.
Read →
 Exploring Zaleplon's Revolutionary R&D Successes
Drug Insights
4 min read
Exploring Zaleplon's Revolutionary R&D Successes
17 September 2023
This article summarized the latest R&D progress of Zaleplon, the Mechanism of Action for Zaleplon, and the drug target R&D trends for Zaleplon.
Read →
Cystic Fibrosis Treatment Drug - CFTR Modulators
Cystic Fibrosis Treatment Drug - CFTR Modulators
17 September 2023
The CFTR protein is an ion channel mainly used to regulate the transepithelial movement of anions in mucus secretion tissues, thereby coordinating the balance of salt and fluid levels in mucus secretions.
Read →